(EMAILWIRE.COM, March 01, 2025 ) The Nuclear Pharmacy Market Size is valued at USD 5.7 Bn in 2023 and is predicted to reach USD 12.8 Bn by the year 2031 at a 10.91 % CAGR during the forecast period for 2024-2031.
Global Nuclear Pharmacy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1980
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Nuclear Pharmacy market are:
Increasing incidence and prevalence of target conditions
Increasing Applications in Oncology and Cardiology
Rising Prevalence of Chronic Diseases
The following are the primary obstacles to the Nuclear Pharmacy market’s expansion:
Technological Complexities and Infrastructure Requirements
Supply Chain Disruptions and Radiopharmaceutical Shortages
Short half-life of radiopharmaceuticals
Future expansion opportunities for the global Nuclear Pharmacy market include:
Growing Demand for Personalized Medicine
Advancements in Nuclear Medicine Technologies
Technological Innovations in Radiopharmaceutical Production
Key Industry Insights & Findings from the report:
The industry is expanding as technology advancements allow radiopharmaceuticals to be used to identify and treat malignant tumors. The increasing prevalence of cancer and cardiovascular disorders, advances in radiopharmaceuticals, and the growing usage of nuclear medicine in diagnostic and therapeutic applications are the key drivers of the nuclear medicine market.
The increased government funding for nuclear medical research and development will drive market growth.
A chronic shortage of skilled healthcare professionals impedes the use of nuclear pharmacy technologies.
North America is expected to have the largest market share in 2024 due to an increase in surgical procedures and a rise in preference for endovascular devices.
Market Analysis:
The market has been influenced by factors such as the rising prevalence of chronic illnesses, advances in nuclear medicine technology, and increased demand for customized medication. Regulatory approvals for new radiopharmaceuticals, expanded applications of nuclear medicine in cancer and neurology, and increased investment in nuclear medicine infrastructure all contribute to the Global Nuclear Pharmacy Market’s growth.
Collaborations between pharmaceutical corporations, research universities, and healthcare providers strive to improve product development, streamline distribution routes, and increase patient access to nuclear medical services globally.
List of Prominent Players in the Nuclear Pharmacy Market:
GE HealthCare
Cardinal Health
Curium
Bayer AG
Lantheus Holdings, Inc.
Bracco Imaging S.p.A.
PharmaLogic Holdings Corp.
Eczacibasi-Monrol Nuclear Products
NTP Radioisotopes SOC Ltd
Nordion Inc.
Novartis (Advanced Accelerator Application)
NorthStar Medical Radioisotopes
Eckert & Ziegler
Isotope JSC
Siemens Healthineers
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Recent Developments:
In January 2023, NorthStar Medical Radioisotopes (US) has made significant progress in developing its novel method for producing molybdenum-99 (Mo-99), a crucial medical radioisotope, without using uranium.
In May 2024, Mauritius launched its new National Cancer Centre in Solferino, marking the completion of nearly 10 years of IAEA support for the country’s nuclear medicine development. The new center is expected to drastically change cancer care for Mauritius patients by consolidating all oncology services, including nuclear medicine, under one roof.
In January 2023, NorthStar Medical Radioisotopes significantly improved their process to create molybdenum-99 without uranium. This strategic move propels the organization to the forefront of the nuclear medicine market while solving important supply chain challenges.
Nuclear Pharmacy Market Dynamics:
Market Drivers: Increasing incidence and prevalence of target conditions
The rising frequency of cancer and cardiovascular illness is a major factor driving market expansion. The majority of instances may be avoided with early identification and treatment; nuclear medicine plays an important role in these areas.
According to the American Heart Association 2022, roughly 19.1 million deaths were related to CVD worldwide in 2020. The age-adjusted mortality rate per 100,000 populations was 239.8, while the age-adjusted prevalence rate was 7354.1 per 100,000. Nuclear medicine plays an important role in illness detection and treatment, and the rising frequency of these disorders is expected to fuel market expansion throughout the forecast period.
Challenges: Technological Complexities and Infrastructure Requirements
Technological difficulties and infrastructural needs provide obstacles in the Global Nuclear Pharmacy Market, especially in emerging regions and resource-constrained settings. Radiopharmaceuticals must be produced and delivered using specific infrastructure, equipment, and experience to assure safe handling, synthesis, quality control, and distribution of radioactive medications.
Establishing and sustaining nuclear pharmacy, cyclotron, and radioisotope manufacturing facilities requires substantial capital commitment, regulatory permissions, and operating skills.
North America Is Expected To Grow With the Highest CAGR during the Forecast Period
North America is frequently considered the area controlling the global nuclear pharmacy market. Several reasons contribute to its dominant position in this sector. North America has cutting-edge healthcare infrastructure, with huge networks of hospitals, clinics, and academic medical institutions outfitted with sophisticated imaging technology and nuclear medicine facilities.
This infrastructure enables the widespread use of nuclear medicine techniques for diagnostic imaging, treatments, and medical research, resulting in increased demand for radiopharmaceuticals and nuclear pharmacy services.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1980
Segmentation of Nuclear Pharmacy Market-
By Type-
Diagnostic Nuclear Medicine
o SPECT Radiopharmaceuticals
Tc-99m
1-123
Tl-201
Ga-67
Other SPECT Isotopes
o PET Radiopharmaceuticals
F-18
Rb-82
Other PET Isotopes
Therapeutic Nuclear Medicine
o Alpha Emitters
Ra-223
o Beta Emitters
1-131
Y-90
Sm-153
Lu-177
Re-186
Other Beta Emitters
Brachytherapy Isotopes
o 1-125
o Ir-192
o Pd-103
o Cs-131
o Other Brachytherapy Isotopes
By Application-
Diagnostic Applications
o SPECT Applications
Cardiology
Bone Scans
Thyroid Applications
Pulmonary Scans
Other SPECT Applications
PET Applications
o Oncology
o Cardiology
o Neurology
o Other PET Applications
Therapeutic Applications
o Thyroid Indications
o Bone Metastasis
o Lymphoma
o Endocrine Tumors
o Other Indications
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
Insight Ace Analytics
Diana Dsouza
+1 551 226 6109
diana.dsouza@insightaceanalytics.com
Source link
